Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats

Ahmed, Hanaa H.; El-Aziem, Sekena H. Abd; Abdel-Wahhab, Mosaad A.

doi:10.1016/j.tox.2007.09.018

Cited by 22 publications

(18 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Indeed, FZD is reported as a mutagenic, genotoxic and potentially carcinogenetic. 46,47 However, MTZ is also listed as a potential carcinogen by FDA and yet it is commonly used worldwide. 45 The sensitivity of H. pylori to furazolidone seems to vary from one geographical region to another.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

Tay

Windsor

Thirriot

et al. 2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

Tay

Windsor

Thirriot

et al. 2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Studies suggested that irreversible damage to the DNA of human epithelial cells (HEp-2) as well as hormone disturbances (reflecting endocrine dysfunction) occurred prevalently when cells were exposed to furazolidone (De Angelis et al, 1999;Ahmed et al, 2008). The majority of the information available describes in vivo studies which utilise mouse and rat models for examination of the effects of furazolidone and mainly nitrofurazone or its residue semicarbazide.…”

Section: Mutagenicity and Toxicity Of Nitrofurans And Semicarbazidementioning

confidence: 99%

Nitrofuran antibiotics: a review on the application, prohibition and residual analysis

Vass¹,

Hruška²,

Fránek³

2008

Vet. Med.

238

130

View full text Add to dashboard Cite

Nitrofuran antibiotics, employed for the treatment of bacterial diseases in livestock production, were banned from use in the European Union (EU) in 1995 due to concerns about the carcinogenicity of their residues in edible tissue. This review provides an overview of nitrofuran toxicity, metabolism, and also specific aspects of legislation surrounding their prohibition. Special attention is devoted to semicarbazide -a nitrofuran metabolite and food contaminant. Analytical procedures for nitrofuran analysis in various matrices and validation requirements for screening and confirmation methods with respect to EU regulations are also reviewed.Keywords: nitrofurans; tissue bound metabolites; semicarbazide; bioavailability; mutagenicity; legislation; sample preparation; validation; detection methods List of abbreviations AHD = 1-aminohydantoin; AOZ = 3-amino-2-oxazolidinone; AMOZ = 3-amino-5-morpholino-methyl-1,3-oxazolidinone; CC α = decision limit; CC β = detection capability; EC = European Commission; EFSA = European Food Safety Authority; ELISA = enzyme linked immuno-adsorbent assay; ESI = electro-spray ionisation; EU = European Union; FTD = furaltadone; FZD = furazolidone; HPLC = high performance liquid chromatography; IC = inhibition concentration; LC = liquid chromatography; LOD = limit of detection; MS = mass spectrometry; NFT = nitrofurantoin; NFZ = nitrofurazone; NP = nitrophenyl; NPAHD = 3-(2-nitrobenzylidenamino)-2,4-imidazolidinedione); NPAMOZ = 5-(morpholinomethyl)-3-(2-nitrobenzylidenamino)-2-oxazolidinone); NPAOZ = [3-(2-nitrobenzylidenamino)-2-oxazolidinone]; NPSEM = 3[(2-nitrophenyl)methylene]-hydrazinecarboxamide; o-NBA = ortho-nitrobenzaldehyde; RASFF = Rapid Alert System for Food and Feed; SE = solvent extraction; SEM = semicarbazide; SPE = solid phase extraction; UV = ultraviolet

show abstract

“…[6] However, some concerns recently arose in using furazolidone, such as a molecule harboring a potential carcinogenetic effect. [7–13]…”

mentioning

confidence: 99%

Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis

Zullo

Ierardi

Hassan

et al. 2012

Saudi J Gastroenterol

View full text Add to dashboard Cite

Background/Aim:Furazolidone-based therapies are used in developing countries to cure Helicobacter pylori infection due to its low cost. The low bacterial resistance toward furazolidone may render appealing the use of this drug even in developed countries. However, some relevant safety concerns do exist in using furazolidone.Patients and Methods:This was a systematic review with pooled-data analysis of data regarding both eradication rate and safety of furazolidone-based therapies for H. pylori infection. Intention-to-treat (ITT) and per-protocol (PP) eradication rates were calculated.Results:Following furazolidone-based first-line therapy, H. pylori eradication rates were 75.7% and 79.6% at ITT and PP analysis, respectively (P<0.001). The overall incidence of side effects and severe side effects were 33.2% and 3.8%, respectively. At multivariate analysis, only high-dose furazolidone was associated with increased therapeutic success (OR: 1.5, 95% CI: 1.3-2.7; P<0.001), while occurrence of side effects was relevant following treatment for a long duration (OR: 2.9, 95% CI: 2.2-4.1; P<0.001), high-dose furazolidone (OR: 2.3, 95% CI: 1.7-3.2; P<0.001) and bismuth-containing regimens (OR: 2.1, 95% CI: 1.5-2.8; P<0.001).Conclusions:Furazolidone-based regimens usually achieve low eradication rates. Only a high-dose regimen improves the cure rate, but simultaneously increases the incidence of severe side effects. Therefore, we suggest that patients have to be clearly informed about the possible genotoxic and carcinogenetic effects for which furazolidone use is not approved in developed countries.

show abstract

Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats

Cited by 22 publications

References 76 publications

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

Nitrofuran antibiotics: a review on the application, prohibition and residual analysis

Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis

Contact Info

Product

Resources

About